Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.76
TRUMY's Cash-to-Debt is ranked lower than
62% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. TRUMY: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
TRUMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.34  Med: 0.82 Max: N/A
Current: 0.76
Equity-to-Asset 0.51
TRUMY's Equity-to-Asset is ranked lower than
63% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. TRUMY: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
TRUMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.59 Max: 0.82
Current: 0.51
0.48
0.82
Interest Coverage 61.56
TRUMY's Interest Coverage is ranked higher than
54% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.93 vs. TRUMY: 61.56 )
Ranked among companies with meaningful Interest Coverage only.
TRUMY' s Interest Coverage Range Over the Past 10 Years
Min: 19.91  Med: 72 Max: 1159.37
Current: 61.56
19.91
1159.37
Piotroski F-Score: 5
Altman Z-Score: 3.17
WACC vs ROIC
2.80%
8.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 15.19
TRUMY's Operating Margin % is ranked higher than
77% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. TRUMY: 15.19 )
Ranked among companies with meaningful Operating Margin % only.
TRUMY' s Operating Margin % Range Over the Past 10 Years
Min: 13.23  Med: 17.08 Max: 21.85
Current: 15.19
13.23
21.85
Net Margin % 7.75
TRUMY's Net Margin % is ranked higher than
65% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.14 vs. TRUMY: 7.75 )
Ranked among companies with meaningful Net Margin % only.
TRUMY' s Net Margin % Range Over the Past 10 Years
Min: 6.26  Med: 10.78 Max: 14.16
Current: 7.75
6.26
14.16
ROE % 7.51
TRUMY's ROE % is ranked higher than
59% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.92 vs. TRUMY: 7.51 )
Ranked among companies with meaningful ROE % only.
TRUMY' s ROE % Range Over the Past 10 Years
Min: 7.03  Med: 10.91 Max: 15.01
Current: 7.51
7.03
15.01
ROA % 4.15
TRUMY's ROA % is ranked higher than
59% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. TRUMY: 4.15 )
Ranked among companies with meaningful ROA % only.
TRUMY' s ROA % Range Over the Past 10 Years
Min: 4.15  Med: 7.04 Max: 11.15
Current: 4.15
4.15
11.15
ROC (Joel Greenblatt) % 19.14
TRUMY's ROC (Joel Greenblatt) % is ranked higher than
63% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.86 vs. TRUMY: 19.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TRUMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 19.14  Med: 28.02 Max: 38.51
Current: 19.14
19.14
38.51
3-Year Revenue Growth Rate 7.30
TRUMY's 3-Year Revenue Growth Rate is ranked higher than
62% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. TRUMY: 7.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TRUMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.4 Max: 12.5
Current: 7.3
0
12.5
3-Year EBITDA Growth Rate 10.60
TRUMY's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. TRUMY: 10.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TRUMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.4 Max: 17.8
Current: 10.6
0
17.8
3-Year EPS without NRI Growth Rate 0.70
TRUMY's 3-Year EPS without NRI Growth Rate is ranked lower than
59% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. TRUMY: 0.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TRUMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.9 Max: 24.9
Current: 0.7
0
24.9
GuruFocus has detected 3 Warning Signs with Terumo Corp $TRUMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TRUMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TRUMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339113 
Compare:NAS:BIOL, NAS:BLFS, NAS:BMRA, NYSE:BAX, NYSE:BDX » details
Traded in other countries:TUO.Germany, 4543.Japan,
Terumo Corp is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. Its products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems & artificial organs.

Terumo Corp was incorporated in Japan on September 17, 1921. The Company is engaged in manufacturing and selling of medical products and equipment, including pharmaceuticals, nutritional food supplement, blood bags, disposable medical devices, cardiovascular systems, vascular grafts, peritoneal dialysis, blood glucose monitoring system, medical electronic, and digital thermometers. The Company operates in business segments including Cardiac & Vascular Business, Blood Management Business, and General Hospital Business. The Cardiac & Vascular Business offers products for vascular interventional treatment including interventional systems for treatment of coronary artery disease & cardiovascular systems for cardiac surgery. The Blood Management Business provides processing management system, including blood bags, leukocyte reduction filters and other equipment's. The General Hospital Business provides products that are used in hospitals on a daily basis include syringes and IV solution products, as well as products that are used by patients at home. The Company geographical segment includes Japan, Europe, Americas, Asia and others.

Ratios

vs
industry
vs
history
PE Ratio 39.94
TRUMY's PE Ratio is ranked lower than
65% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.58 vs. TRUMY: 39.94 )
Ranked among companies with meaningful PE Ratio only.
TRUMY' s PE Ratio Range Over the Past 10 Years
Min: 13.9  Med: 26.24 Max: 43.78
Current: 39.94
13.9
43.78
PE Ratio without NRI 39.94
TRUMY's PE Ratio without NRI is ranked lower than
65% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. TRUMY: 39.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
TRUMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.9  Med: 26.24 Max: 43.78
Current: 39.94
13.9
43.78
Price-to-Owner-Earnings 64.17
TRUMY's Price-to-Owner-Earnings is ranked lower than
80% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.68 vs. TRUMY: 64.17 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TRUMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.53  Med: 56.76 Max: 347.6
Current: 64.17
20.53
347.6
PB Ratio 2.69
TRUMY's PB Ratio is ranked higher than
58% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.39 vs. TRUMY: 2.69 )
Ranked among companies with meaningful PB Ratio only.
TRUMY' s PB Ratio Range Over the Past 10 Years
Min: 1.52  Med: 2.28 Max: 3.58
Current: 2.69
1.52
3.58
PS Ratio 3.12
TRUMY's PS Ratio is ranked lower than
52% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. TRUMY: 3.12 )
Ranked among companies with meaningful PS Ratio only.
TRUMY' s PS Ratio Range Over the Past 10 Years
Min: 1.38  Med: 2.53 Max: 14.78
Current: 3.12
1.38
14.78
EV-to-EBIT 26.75
TRUMY's EV-to-EBIT is ranked lower than
66% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.63 vs. TRUMY: 26.75 )
Ranked among companies with meaningful EV-to-EBIT only.
TRUMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.7  Med: 17.35 Max: 84.4
Current: 26.75
11.7
84.4
EV-to-EBITDA 26.75
TRUMY's EV-to-EBITDA is ranked lower than
81% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.65 vs. TRUMY: 26.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
TRUMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.8  Med: 16.7 Max: 84.4
Current: 26.75
8.8
84.4
PEG Ratio 4.03
TRUMY's PEG Ratio is ranked lower than
67% of the 55 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.82 vs. TRUMY: 4.03 )
Ranked among companies with meaningful PEG Ratio only.
TRUMY' s PEG Ratio Range Over the Past 10 Years
Min: 1.54  Med: 4.91 Max: 9.58
Current: 4.03
1.54
9.58
Shiller PE Ratio 66.88
TRUMY's Shiller PE Ratio is ranked lower than
76% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.61 vs. TRUMY: 66.88 )
Ranked among companies with meaningful Shiller PE Ratio only.
TRUMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 64.88  Med: 68.21 Max: 73.31
Current: 66.88
64.88
73.31
Current Ratio 1.94
TRUMY's Current Ratio is ranked lower than
63% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.37 vs. TRUMY: 1.94 )
Ranked among companies with meaningful Current Ratio only.
TRUMY' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 2.35 Max: 4.1
Current: 1.94
0.83
4.1
Quick Ratio 1.54
TRUMY's Quick Ratio is ranked lower than
56% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. TRUMY: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
TRUMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.75 Max: 3.14
Current: 1.54
0.61
3.14
Days Inventory 157.17
TRUMY's Days Inventory is ranked lower than
66% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. TRUMY: 157.17 )
Ranked among companies with meaningful Days Inventory only.
TRUMY' s Days Inventory Range Over the Past 10 Years
Min: 124.64  Med: 132.21 Max: 157.17
Current: 157.17
124.64
157.17
Days Payable 9.65
TRUMY's Days Payable is ranked lower than
96% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.97 vs. TRUMY: 9.65 )
Ranked among companies with meaningful Days Payable only.
TRUMY' s Days Payable Range Over the Past 10 Years
Min: 8.29  Med: 82.1 Max: 86.88
Current: 9.65
8.29
86.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.09
TRUMY's Dividend Yield % is ranked lower than
58% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.16 vs. TRUMY: 1.09 )
Ranked among companies with meaningful Dividend Yield % only.
TRUMY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.57  Med: 0.93 Max: 1.46
Current: 1.09
0.57
1.46
Dividend Payout Ratio 0.40
TRUMY's Dividend Payout Ratio is ranked lower than
61% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. TRUMY: 0.40 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TRUMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.15  Med: 0.18 Max: 0.4
Current: 0.4
0.15
0.4
3-Year Dividend Growth Rate 20.00
TRUMY's 3-Year Dividend Growth Rate is ranked higher than
68% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.10 vs. TRUMY: 20.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TRUMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17 Max: 33
Current: 20
0
33
Forward Dividend Yield % 1.02
TRUMY's Forward Dividend Yield % is ranked lower than
61% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. TRUMY: 1.02 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.55
TRUMY's 5-Year Yield-on-Cost % is ranked higher than
53% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.53 vs. TRUMY: 2.55 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TRUMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.33  Med: 2.17 Max: 3.41
Current: 2.55
1.33
3.41
3-Year Average Share Buyback Ratio 1.50
TRUMY's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. TRUMY: 1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TRUMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: 0.7 Max: 0
Current: 1.5
-1.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.90
TRUMY's Price-to-Tangible-Book is ranked lower than
63% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. TRUMY: 6.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TRUMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.7  Med: 5.03 Max: 9.22
Current: 6.9
2.7
9.22
Price-to-Intrinsic-Value-Projected-FCF 3.39
TRUMY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
70% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. TRUMY: 3.39 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TRUMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.53  Med: 1.94 Max: 3.99
Current: 3.39
1.53
3.99
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.73
TRUMY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
86% of the 21 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.07 vs. TRUMY: 3.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.23
TRUMY's Price-to-Median-PS-Value is ranked lower than
54% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. TRUMY: 1.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TRUMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 0.99 Max: 5.27
Current: 1.23
0.63
5.27
Price-to-Peter-Lynch-Fair-Value 5.41
TRUMY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
83% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. TRUMY: 5.41 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TRUMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.67  Med: 2.88 Max: 6.78
Current: 5.41
0.67
6.78
Price-to-Graham-Number 3.50
TRUMY's Price-to-Graham-Number is ranked lower than
67% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. TRUMY: 3.50 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TRUMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.64  Med: 2.35 Max: 3.77
Current: 3.5
1.64
3.77
Earnings Yield (Greenblatt) % 3.74
TRUMY's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. TRUMY: 3.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TRUMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 5.8 Max: 8.6
Current: 3.74
1.2
8.6
Forward Rate of Return (Yacktman) % 7.39
TRUMY's Forward Rate of Return (Yacktman) % is ranked lower than
60% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. TRUMY: 7.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TRUMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.2  Med: -5.9 Max: 11.8
Current: 7.39
-11.2
11.8

More Statistics

Revenue (TTM) (Mil) $4,624
EPS (TTM) $ 0.92
Beta0.19
Short Percentage of Float0.00%
52-Week Range $33.90 - 46.00
Shares Outstanding (Mil)362.97
» More Articles for TRUMY

Headlines

Articles On GuruFocus.com
Abbott Closes St. Jude Medical Deal Wednesday Jan 03 2017 
Abbott Labs to Buy St. Jude Medical for $25 Billion Dec 28 2016 
Abbott: $15 Billion Available From Notes Nov 25 2016 
Abbott, St. Jude Medical: vascular closure products sale's agreement Oct 20 2016 
Hennessy Japan Fund Trims 14 Holdings Oct 06 2016 
Hennessy Japan Fund Top Q3 Stock Adds and Reductions Oct 04 2014 
Hennessy Japan Fund Comments on Terumo Corp Jun 26 2014 
Hennessy Japan Fund Semi-Annual Report April 30, 2014 Jun 26 2014 

More From Other Websites
Terumo Showcases Radial Access Portfolio at American College of Cardiology Conference Mar 17 2017
MicroVention® And Terumo Corporation Announce Data From Multicenter GREAT Study Mar 07 2017
Terumo Corp. :TRUMY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 10, 2017 Feb 10 2017
Terumo Corp. :TRUMY-US: Earnings Analysis: Q2, 2017 By the Numbers : November 14, 2016 Nov 14 2016
ETF’s with exposure to Terumo Corp. : November 1, 2016 Nov 01 2016
Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership Sep 12 2016
ETF’s with exposure to Terumo Corp. : September 8, 2016 Sep 08 2016
ETF’s with exposure to Terumo Corp. : August 26, 2016 Aug 26 2016
Terumo Corp. :TRUMY-US: Earnings Analysis: Q1, 2017 By the Numbers : August 9, 2016 Aug 09 2016
Terumo Corp. :TRUMY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Terumo Corporation Completes Acquisition Of Sequent Medical Jul 14 2016
Terumo Corporation Acquires Sequent Medical Jun 15 2016
FDA Lifts All Remaining Shipping Restrictions at Terumo Cardiovascular Systems' Ann Arbor Facility Jun 10 2016
Terumo Corp. :TRUMY-US: Earnings Analysis: Q4, 2016 By the Numbers May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)